New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:50 EDTBIOS, VICL, IPCI, ALIM, CBMXVical, CombiMatrix poised for breakouts, says
In a report on stocks with technical attributes that indicate they may be poised for a near-term breakout, TheStreet's Roberto Pedone identifies CombiMatrix (CBMX), Vical (VICL), Intellipharmaceutics (IPCI), BioScrip (BIOS) and Alimera Sciences (ALIM). Reference Link
News For VICL;CBMX;IPCI;BIOS;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
11:47 EDTIPCIIntellipharmaceutics path for Rexista significantly shorter, says Brean Capital
Subscribe for More Information
08:14 EDTIPCIIntellipharmaceutics intends to accelerate Rexista Oxycodone XR program
Intellipharmaceutics announced that the FDA provided the company with notification regarding its Investigational New Drug Application, or IND, submission for Rexista Oxycodone XR extended release tablets. The notification from the FDA stated that the Company will not be required to conduct Phase III studies if bioequivalence to Oxycontin is demonstrated. The company had earlier announced, on March 30, that it had submitted an IND to the FDA for Rexista Oxycodone XR in anticipation of the commencement of Phase III clinical trials. At the same time the Company had also announced that topline data results of three definitive Phase I pharmacokinetic clinical trials all met the bioequivalence criteria when compared to the existing branded drug Oxycontin. The company believes, in light of these prior results, that it will not be required to conduct Phase III studies, although no assurance to that effect can be given. The company believes the FDA notification is significant as it provides a basis for an accelerated development plan for its Rexista Oxycodone XR product candidate, without the need for more costly and time-consuming Phase III studies. The company intends to file a New Drug Application, or NDA, for Rexista Oxycodone XR extended release tablets with the FDA within the next 6 to 12 months, although no assurance to this effect can be given. Further, there can be no assurance that the FDA will ultimately approve the NDA for sale of Rexista Oxycodone XR in the U.S. market, or that it will ever be successfully commercialized.
06:32 EDTVICLVical completes enrollment in Phase 2 clinical trial of CMV vaccine
Subscribe for More Information
May 13, 2015
14:33 EDTBIOSGabelli raises stake in BioScrip to 16.43% from 15.15%
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use